What Happened?
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved its romidepsin injection solution, a treatment used in certain lymphoma patients.
The newly approved cancer therapy will be supplied in single-dose, ready-to-use vials, a design meant to simplify use in hospitals. Crucially, the product was granted Competitive Generic Therapy (CGT) status, giving Amneal 180 days of market exclusivity.
According to IQVIA data, U.S. annual sales for the original version of the drug were approximately $78 million for the 12 months ended April 2026. Investors view this approval as a key step that could expand Amneal's injectable oncology portfolio and support future revenue growth.
Is now the time to buy Amneal? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Amneal’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 7 months ago when the stock gained 8.9% on the news that the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast.
The pharmaceutical company posted adjusted earnings of $0.17 per share for the quarter, beating analyst estimates. Revenue also topped forecasts, reaching $785 million, which represented a 12% increase compared to the same period in the prior year.
Bolstered by these results, Amneal provided an improved outlook for the full year. The company revised its projections for net revenue to a range between $3.0 billion and $3.1 billion and lifted its forecast for adjusted earnings per share to between $0.75 and $0.80.
Amneal is up 7.6% since the beginning of the year, but at $13.63 per share, it is still trading 10.3% below its 52-week high of $15.19 from February 2026. Investors who bought $1,000 worth of Amneal’s shares 5 years ago would now be looking at an investment worth $2,495.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
